P116 Histone deacetylase 1: a novel therapeutic target for patients with rheumatoid arthritis. (21st February 2018)

• Record Type: Journal Article
• Authors: Göschl, L; Müller, L; Saferding, V; Bäcklund, J; Knapp, S; Mathias, P; Scheinecker, C; Ellmeier, W; Steiner, G; Bonelli, M
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 1
• Page Start: A63
• Page End: A63
• Publication Date: 2018-02-21
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-EWRR2018.131
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Introduction: Despite enormous efforts to develop new therapeutic strategies for treatment of rheumatoid arthritis (RA), the large number of non responding patients to currently available drugs underlies the unmet need to identify new therapeutic targets. Certain CD4 + T cells have been shown to be major drivers of inflammation in patients with RA. The expression of their key transcription factors is controlled by histone modifications which includes acetylation of lysine residues mediated by histone deacetylases (HDAC). Indeed, pan HDAC inhibitors have been shown to be a potential therapeutic strategy in the treatment of malignancies. However, major side effects limited the clinical use and underline the need of more specific HDAC inhibitors. Recent data suggest a role of HDAC1 on the migratory capacity and the differentiation of CD4 + T cells in the context of autoimmune encephalitis. 1 Objectives: Our aim was to elucidate the individual role of HDAC1 in a T cell dependent arthritis model, namely the collagen-induced arthritis model (CIA). Methods: Mice with a T cell specific deletion of HDAC1 (HDAC1 cKO) were generated by using the CD4Cre/LoxP system. At week 8 of age arthritis was induced in wild type (WT) and HDAC1 cKO mice by immunising with chicken collagen II (CII), emulsified in complete Freund´s adjuvant. The animals were scored for clinical signs of arthritis, namely paw swelling and grip strength. Anti-CII antibody levels were determined by ELISA. Various cell subsets, including Th cells, where detected in the blood, the spleen and the draining lymph node by FACS analysis. To test antigen-specific T cell activation we performed in vitro restimulation of spleen and lymph node cells with collagen II followed by assessment of cytokine production and quantification of the proliferation rate using 3 H-thymidine incorporation. After 10 weeks mice were sacrificed and paraffin sections of the affected joints were analysed for histomorphologic signs of inflammation, cartilage and bone destruction. Results: Eighty percent of the animals developed serum anti-CII anibodies (IgM and IgG). No difference in the production of antibody subclasses, especially of pathogenic IgG2c antibodies, were observed between WT and HDAC1 cKO mice. Surprisingly, HDAC1 cKO mice were completely protected and did not develop any clinical signs of arthritis. Accordingly, histological analysis revealed no signs of inflammation, no bone erosion and no appearance of osteoclasts in the joints of HDAC1 cKO mice. In line with our recently published data on the role of HDAC1 on the differentiation and migration of T cell subsets we suggest that HDAC1 plays a key role in the development of arthritis. Conclusions: Our data show the importance of HDAC1 as a key immune regulator in the pathogenesis of T cell driven collagen induced arthritis. Therefore it might be considered as an interesting novel therapeutic target in RA. Reference: . Goschl L, et al. A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis. J Autoimmun2017. Disclosure of interest: None declared